Comparison of systems for evaluating the effectiveness of modern immunotherapy
- Authors: Oganesyan A.P1, Protsenko S.A1, Baldueva I.A1, Novik A.V1,2, Latipova D.K.1, Semenova A.I1, Teletaeva G.M1
-
Affiliations:
- N.N. Petrov National Medical Research Center of Oncology
- St. Petersburg State Pediatric Medical University
- Issue: Vol 27, No 7 (2020)
- Pages: 58-61
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312718
- DOI: https://doi.org/10.18565/pharmateca.2020.7.58-61
- ID: 312718
Cite item
Abstract
Keywords
Full Text
About the authors
A. P Oganesyan
N.N. Petrov National Medical Research Center of Oncology
Email: Ani101192@mail.ru
Oncologist, Postgraduate Student at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation
S. A Protsenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. A Baldueva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. V Novik
N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
D. Kh Latipova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. I Semenova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. M Teletaeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
References
- Livingstone A., Agarwal A., Stockier M.R., et al. Preferences for Immunotherapy in Melanoma: A Systematic Review, Ann Surg Oncol. 2019 Oct 29. Do:: 10.1245/s10434-019-07963-y.
- Sharma P, Allison J.P The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172.
- Ferrara R., Mezquita L., Texier M., et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD- 1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543-52.
- Nishino M, Hatabu H., Hodi F.S. Imaging of cancer immunotherapy: current approaches and future directions. Radiology. 2019;290(1):9-22.
- Katz S.I., Hammer M., Bagley S.J., et al. Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(7):978-86.
- Nishino M, Giobbie-Hurder A., Manos M.P, et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res. 2017;23(16):4671-79.
- Kim J.H. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysisandreview. Oncotarget. 2016;7(12):13680-87. doi: 10.18632/oncotarget.7322.
- Wolchok J.D., Hoos A., O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624.
- Bhanusupriya Somarouthu, Susanna I Lee, Trinity-Urban. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91(1084):20170457.
- Nishino M., Gargano M., Suda M., et al. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17. doi: 10.1186/2051-1426-2-17.
- Spiro J., Maintz D., Persigehl T Response criteria for malignant melanoma: RECIST and irRC. Radiologe. 2015;55(2):127-35. doi: 10.1007/s00117-014-2763-y.
- Hodi F.S., Hwu W.J., Kefford R., et al. Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). J Clin Oncol. 2016;34(13):1510-17. Doi: 10.1200/ JCO.2015.64.0391.
- Di Giacomo A.M., Danielli R., Guidoboni M., et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297-306. Doi: 10.1007/ s00262-008-0642-y.